Supportive Medicines Prcourement (Phase 1 Part 2)

CPV: Pharmaceutical products

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Goods

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Yes (GPA)

Recurring procurement

Unspecified in notice

First published

5 Mar 2021, 22:44 GMT

Last source update

5 Mar 2021, 22:44 GMT

Authority reference

CM-EMI-20-C12180

FTS notice number

2021/S 000-004515

Classification (CPV)

Pharmaceutical products

Delivery area

UK

Official registry OCID

ocds-h6vhtk-029914 Find a Tender

Why no open competition

Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive

Published justification

The Coronavirus disease (COVID-19) is a serious infectious respiratory disease and its consequences pose a risk to life. The WHO Director General characterised COVID-19 as a pandemic on 11 March 2020, by this stage Europe was at the centre of the pandemic.During the initial response to the Covid-19 virus (the virus) and due to high global demand, there was concern around the availability of certain medicines used in intensive treatment units and for end of life care (the medicines) and there was a focus on ensuring the medicines would continue to be available to avoid the NHS running out and the impact of this on public health. Although wave 1 of the virus had subsided, the Contracting Authority was expecting and planning for an imminent second wave, and anticipated that the high global demand for the supplies of the medicines would be similar to wave 1. The Contracting Authority, having identified suppliers that were ready, willing and able to supply the medicines, needed to move quickly to secure the available supply. Failure to do this would have resulted in the medicines being sold by the suppliers to another country due to the high global demand. It was imperative to maintain security of supply for public health purposes. In these circumstances, a procurement following the usual timescales under the PCR 2015, including accelerated options, was not feasible in order for the Contracting Authority to secure sufficient supply of the Medicines. The contracts are for the benefit of the Authority and NHS Bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies and the local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health-related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers.

Publisher note: The contracts are for the benefit of theAuthority and NHS Bodies along with anyother non-NHS bodies which are necessaryfor the delivery of services or goods to NHSbodies and the local authorities, othergovernment departments or nondepartmentalpublic bodies charged withthe delivery of healthcare or health-relatedservices in the United Kingdom, CrownDependencies and British OverseasTerritories including, without limitation, theNational Assembly for Wales, the NorthernIreland Assembly, and Scottish Ministers.

• Accord-UK LtdAwarded supplier79585 Whiddon Valley, Barnstaple, UK, EX32 8NS
• Fresenius Kabi LimitedAwarded supplier Runcorn, UK
• Kent Pharma LtdAwarded supplier Heathrow, UK
• Piramal Critical care LimitedAwarded supplier Uxbridge, UK

No document links were published on the notice.